What is Bladder Cancer?
Bladder cancer is a urological neoplasm that occurs in the tissues of the bladder. It is characterized by a rapid and uncontrolled growth of cells of the epithelial lining and can proliferate in the muscular wall of the bladder. The bladder is a hollow organ located in the pelvis (lower abdomen) that stores urine drained by the kidneys. It is connected to the kidney by the ureters, a tube-like structure. Bladder cancer is the ninth most commonly diagnosed cancer. Regions such as North America, Western and Southern Europe, as well as some countries in Western Asia and North Africa have had the highest incidence rates among men. Bladder cancer is more common in men than in women, however, the sex ratio varies by country.
The exact causes of bladder cancer are not known. However, it is considered that some of the risk factors such as excessive smoking, continued exposure to radiation, chronic bladder infection and previous cancer treatments can cause bladder cancer. Bladder cancer can affect any age group. However, it is more prevalent in adults over 50 years of age. In addition, trends around the world reflect smoking as the leading cause of bladder cancer. Infection with Schistosoma Haematobium and other risk factors are also the main causes of bladder cancer in a given population.
Global Bladder Cancer Market Size:
According to the report published by Research Cosmos, the Global Bladder Cancer Market Size Estimated to reach USD 5 Billion by 2025 growing at an impressive CAGR.
What are the factors driving growth for Global Bladder Cancer Market?
The global market for bladder cancer is based on the increasing incidence of tumors, innovations of drugs for treatment and advances in technology. As this cancer is more common in adults over 50 years, the increase in the geriatric population also contributes to the growth of the market. In addition, government initiatives, increased awareness of bladder cancer and available treatments, as well as progressive health services associated with increased spending on health care also boost the global market. Since cancer is an asymptomatic disease in the initial stage, it requires an accurate diagnosis at an early stage. An inaccurate and unaffordable diagnosis could lead to serious complications, resulting even in death
Geographical Insights:
The global bladder cancer market can be segmented by diagnosis, therapy and region. Bladder cancer can be diagnosed by urine laboratory tests, cystoscopy, biopsy and imaging. Urinalysis can be subdivided into urinalysis, urine cytology, and urine culture and urine tumor marker test. In terms of therapy, the market can be segmented into chemotherapy, radiotherapy, immunotherapy and surgery.
Geographically, the bladder cancer market can be segmented into five major regions like North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa. North America leads the world market for bladder cancer. Most of the region is attributed to an increased incidence of bladder cancer, innovative healthcare solutions, an advanced healthcare infrastructure and growing concern about bladder problems. Europe represents the second largest market share. The global bladder cancer market in Asia-Pacific is expected to experience strong growth. This increase is mainly due to the growing awareness of bladder diseases and innovative diagnostic and treatment options. The main market players believe that Asian countries are lucrative markets for bladder cancer and are making significant investments, leading to market growth.
Leading companies in the market analyzed in the report are:
About Research Cosmos:
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
Contact Us:
Kevin Stewart
Sales Manager
Research Cosmos
# +1 888 709 8757